All In Biotech

Drug Trial Radar · NCT05291286

BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients

A Pilot Proof of Concept Pharmacokinetic/Pharmacodynamic Study of BXQ-350 in Cancer Patients Exposed to Oxaliplatin and/or Taxane-Based Chemotherapy

Last checked: Nov 20, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

21

Actual

Start

Oct 17, 2022

Primary completion

Dec 20, 2024

Study completion Dec 20, 2024

Sponsor

Lead sponsor
Bexion Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
CTI Clinical Trial and Consulting Services
First posted
Mar 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Supportive care
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess pharmacokinetic (PK)/pharmacodynamic (PD) relationships and whether BXQ-350 may decrease the intensity and/or duration of chemotherapy induced peripheral neuropathy (CIPN) thereby improving quality of life (QoL) in cancer patients who have been exposed to oxaliplatin and/or taxane-based chemotherapy. This study includes two randomized, placebo controlled, blinded treatment cycles of BXQ-350/placebo, an optional open-label BXQ-350 treatment period, and an unblinded Post-Treatment Follow-up period.

Conditions

  • Neuropathy;Peripheral
  • Chemotherapy-induced Peripheral Neuropathy

Interventions

  • BXQ-350Drug

    BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 will be administered by intravenous (IV) infusion

  • PlaceboOther

    Placebo will be 0.9% normal saline of matching volume to BXQ-350 administered by intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak Plasma Concentration (Cmax)Time frame: 6 months
  2. CeramideTime frame: 6 months
  3. S1P levelsTime frame: 6 months
  4. Cytokine levelsTime frame: 6 months
  5. Quality of Life (QoL)Time frame: 6 months
  6. Total Sensory NeuropathyTime frame: 6 months
  7. CIPN AssessmentTime frame: 6 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • CTI Clinical Research Center

    Cincinnati, Ohio

  • The Ohio State Unviersity

    Columbus, Ohio

  • Vanderbilt University Medical Center

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.